MYOMO, INC.
About MYOMO, INC.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $40.9M
- Net income
- -$15.6M
- Total assets
- $38.6M
- Market cap
- $49.5M
- Gross margin
- 65.7%
- Operating margin
- -35.2%
- Net margin
- -38.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $40.9M
- Cost of revenue
- $14.0M
- Gross profit
- $26.9M
- Operating expenses
- $41.3M
- Operating income
- -$14.4M
- Income tax
- $504.5K
- Net income
- -$15.6M
- EPS (basic)
- $-0.37
- EPS (diluted)
- $-0.37
Balance sheet
- Total assets
- $38.6M
- Current assets
- $27.6M
- Total liabilities
- $27.2M
- Current liabilities
- $8.3M
- Shareholders’ equity
- $11.4M
Cash flow
- Operating cash flow
- -$14.5M
- Investing cash flow
- -$7.1M
- Financing cash flow
- $11.4M
- Net cash flow
- -$10.1M
Statements via Polygon.io (SEC filings)
- Market cap
- $49.5M
- EPS (diluted)
- $-0.37
- Shares outstanding
- 38.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 12, 2017
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $15.6M in FY2025.
- Revenue grew 195% from FY2021 to FY2025.
- Gross margin of 65.7%, net margin -38.1%.
- Trading 74% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review MYOMO, INC..
Write a review
News about MYOMO, INC.
News & sentiment via Polygon.io
